(Q37673201)

English

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

scientific article published on 03 March 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

randomized controlled trial

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

11

object named as

Fred Saad

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

15

object named as

Eric J Small

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

2

object named as

Susan Halabi

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

author name string

Matthew R Smith

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Charles J Ryan

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Arif Hussain

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Nicholas Vogelzang

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Walter Stadler

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Ralph J Hauke

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

J Paul Monk

8

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Philip Saylor

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Nirmala Bhoopalam

10

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Ben Sanford

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

W Kevin Kelly

13

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Michael Morris

14

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

0 references

publication date

3 March 2014

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

1143-1150

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Intermittent versus continuous androgen deprivation in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Emerging therapies to prevent skeletal morbidity in men with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

NCCN Task Force Report: Bone Health in Cancer Care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

23 August 2017

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

25 June 2018

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

25 June 2018

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

1 September 2018

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

1 September 2018

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3970172

1 September 2018

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24590644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.51.6500

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37673201&oldid=2186440885"